

BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

Overview

2024/07/17 08:10:06	
Price	6.836 EUR
Difference	<div><div></div></div> 2.91% (0.19)

General attributes	
ISIN	CA0717341071
Symbol	BHC
Exchange	Duesseldorf
Currency	EUR
Sector	Other
Security type	Stock
Market cap (m)	2,540 EUR
Benchmark	S&P/TSX 60 INDEX

Market data	
Bid (Bid size)	6.796 EUR (500)
Ask (Ask size)	6.925 EUR (500)
Open	6.836 EUR
High	6.836 EUR
Low	6.836 EUR
Close (prev. day)	6.643 EUR
VWAP	-
Volume (pcs)	0
Trading volume	0.00
Number of trades	1
Last size	0

Futures and Options	
Related Futures	15
Related Options	-

PDF Downloads	
Company report: BAUSCH HEALTH COMPANIES INC.	<div><div></div></div>




Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

on sector			
Date		Headline	Download
2024/07/12		Global Equity Ratings	<div><div></div></div>
2024/06/21		Global Equity Ratings	<div><div></div></div>
2024/06/14		Global Equity Ratings	<div><div></div></div>
2024/05/29		Global Equity Ratings	<div><div></div></div>
2024/04/26		Global Equity Ratings	<div><div></div></div>

Details

2024/07/17 08:10:06		
Price	6.836 EUR	
Difference		2.91% (0.19)

General attributes	
ISIN	CA0717341071
Symbol	BHC
Exchange	Duesseldorf
Currency	EUR
Sector	Other
Security type	Stock
Market cap (m)	2,540 EUR
Benchmark	S&P/TSX 60 INDEX

Market data	
Bid (Bid size)	6.796 EUR (500)
Ask (Ask size)	6.925 EUR (500)
Open	6.836 EUR
High	6.836 EUR
Low	6.836 EUR
Close (prev. day)	6.643 EUR
VWAP	-
Volume (pcs)	0
Trading volume	0.00
Number of trades	1
Last size	0

Performance and Risk			
	6m	1Y	3Y
Perf (%)	-13.11%	-10.46%	-71.67%
Perf (abs.)	-1.00	-0.78	-16.81
Beta	1.12	1.23	1.76
Volatility	41.56	43.60	74.41



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	6.696 EUR (0)
Ø price 30 days Ø volume 30 days (pcs.)	6.183 EUR (0)
Ø price 100 days Ø volume 100 days (pcs.)	7.277 EUR (6)
Ø price 250 days Ø volume 250 days (pcs.)	7.272 EUR (2)
YTD High date	9.790 EUR (2024/04/02)
YTD Low date	5.545 EUR (2024/05/30)
52 Weeks High date	9.790 EUR (2024/04/02)
52 Weeks Low date	5.545 EUR (2024/05/30)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/07/16	22:26	6.931 EUR	0.00	1
Toronto Stock Exchange	2024/07/16	22:00	10.32 CAD	4.49	2,497
Stuttgart	2024/07/17	09:29	6.831 EUR	0.00	2
SIX Swiss Exchange	2019/06/28	17:35	24.11 CHF	0.00	1
NYSE	2024/07/16	22:00	7.55 USD	34.04	17,773

	16						
Munich	2024/07/17	08:01	6.843	EUR	0.00		1
Frankfurt	2024/07/17	08:14	6.84	EUR	0.00		1
Duesseldorf	2024/07/17	08:10	6.836	EUR	0.00		1
Berlin	2024/07/17	08:01	6.843	EUR	0.00		1

Company profile

Company Logo



Contact Details

BAUSCH HEALTH COS. INC.

--

2150 St. Elzéar Boulevard West - H7L 4A8
Laval

Telefon: +1-514-744-6792

Fax: +

E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH
COMPANIES INC.



Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Members of Management Board

Thomas Appio	Chairman of Managing Board
Tage Ramakrishna	Member of Executive Committee
Cees Heiman	Member of Executive Committee
Fernando Zarate	Member of Executive Committee
Graham Jackson	Member of Executive Committee
Jeff Hartness	Member of Executive Committee
Kathleen Fitzpatrick	Member of Executive Committee
Mirza Dautbegovic	Member of Executive Committee
Seana Carson	Member of Executive Committee
Tom Vadaketh	Member of Executive Committee

Board of directors

John Paulson	Chairman of Supervisory Board
Amy Wechsler	Member of Supervisory Board
Richard Mulligan	Member of Supervisory Board
Brett Icahn	Member of Supervisory Board
Christian Garcia	Member of Supervisory Board
Frank Lee	Member of Supervisory Board
Robert Power	Member of Supervisory Board
Sarah Kavanagh	Member of Supervisory Board
Steven Miller	Member of Supervisory Board